To present real‐world adalimumab (ADA) efficacy and safety outcomes in non‐infectious uveitis (NIU) from a single United Kingdom (UK) tertiary centre. Click to show full abstract
To present real‐world adalimumab (ADA) efficacy and safety outcomes in non‐infectious uveitis (NIU) from a single United Kingdom (UK) tertiary centre.
               
Click one of the above tabs to view related content.